A Phase 3 interventional study of Pacibekitug and Placebo in Myocardial Infarction, sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Myocardial Infarction by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Myocardial Infarction · Novartis.
Among the 17 studies in Myocardial Infarction by Novartis, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 in phase 3, and was the 17th registered.
2,272 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →2 of the 17 studies in Myocardial Infarction by Novartis are open now, in 1 country. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Russia
Ages 18–100
By country, each count listing its studies:
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 150 across 1,315 interventional studies indexed under Myocardial Infarction.
Median enrollment 5,700 across the 13 interventional studies, 62,159 across the 4 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Myocardial Infarction by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07142265Novartis PharmaceuticalsEvaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Myocardial Infarction by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to demonstrate the superiority of pacibekitug compared to placebo in reducing the risk of 3-point coronary major adverse cardiovascular events (3P-Coronary- MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization, in participants after an MI, at high cardiovascular (CV) risk and receiving standard of care (SoC) secondary CV prevention therapies.
Randomized, double-blind, parallel group, placebo-controlled, multi-center, global, event-driven study evaluating pacibekitug compared to placebo.
The study will consist of an optional pre-screening period of up to \~ 15 days, a screening period of up to \~ 30 days, a double-blind treatment period and a safety follow-up call.
The study is event-driven and designed to complete when both criteria are met: (a) at least 860 participants have experienced a CEC-confirmed primary 3P-Coronary-MACE across both treatment arms, (b) at least 85% of participants have been followed for at least 1 year during the double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria are as follows:
Diagnosis of spontaneous (type 1) MI based on medical records and the Investigator's judgment. Patients must be either:
At high CV risk, defined as the presence of at least two of the following criteria documented in the medical records :
Exclusion Criteria:
The key exclusion criteria are as follows:
Patients with the following laboratory abnormalities at Screening:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pacibekitug s.c.
Drug: Pacibekitug
Placebo s.c.
Drug: Placebo
pacibekitug s.c.
Also known as: PAC001, TOUR006
Placebo s.c.
Time to the first occurrence of 3P-Coronary-MACE
3-point Coronary major adverse cardiovascular events (3P-Coronary-MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization
Time frame: Up tp 1398 days
Time to the first occurrence of 4P-MACE
4P-MACE (composite of CV death, non-fatal MI, non-fatal ischemic stroke, and urgent coronary revascularization)
Time frame: Up tp 1398 days
Time to the first occurrence of 3P-MACE
3-point MACE (3P-MACE) defined as a composite of CV death, non-fatal MI, and non-fatal ischemic stroke
Time frame: Up tp 1398 days
Time to the first occurrence of 4P-MACE or MALE
4P-MACE or Major Adverse Limb Events (MALE) defined as a composite of CV death, non-fatal MI, non-fatal ischemic stroke, urgent coronary revascularization, acute limb ischemia, major amputation of vascular cause, and limb revascularization
Time frame: Up tp 1398 days
Time to the first occurrence of 5P-MACE
5P-MACE defined as a composite of CV death, non-fatal MI, non-fatal ischemic stroke, urgent coronary revascularization, and heart failure \[HF\] hospitalization or urgent visit
Time frame: Up tp 1398 days
Total number of 3P-Coronary-MACE
Times to the occurrences of all 3P-Coronary-MACE (first and recurrent non-fatal MI and urgent coronary revascularization, and occurrence of CHD death).
Time frame: Up tp 1398 days
Total number of 4P-MACE
Times to the occurrences of all 4P-MACE (first and recurrent non-fatal MI, non-fatal ischemic stroke, and urgent coronary revascularization, and occurrence of CV death)
Time frame: Up tp 1398 days
Time to CV death
Time to cardiovascular (CV) death
Time frame: Up tp 1398 days
Time to all-cause mortality
Time frame: Up tp 1398 days
Number of participants with adverse events
Number of participants with AEs, SAEs, AEs leading to discontinuation of study treatment, including abnormal safety laboratory parameters
Time frame: Up tp 1398 days
Percent change from baseline in hsCRP
Percent change from baseline in High-sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, month 6
No study locations are listed for this record.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Oct 2030, 46 months later.
Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.